Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus NAFAZAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus NAFAZAIR.
ADVAIR DISKUS 100/50 vs NAFAZAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing cAMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
2.5 mg subcutaneously once daily.
None Documented
None Documented
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Category C
Category C
Corticosteroid/LABA Combination
Intranasal Antihistamine/Corticosteroid